Public Market Listing
4552TSE
Live quotes, historical charts, and market capitalization for JCR Pharmaceuticals are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(3 total)
3Total Assets
2Approved
1Phase 3 / Filed
0Phase 1–2 / Early
5Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | HDACSmall molecule | Duchenne Muscular DystrophyPolycythemia Vera | |
remestemcel-L(Ryoncil) | Approved | Allogeneic MSC therapyCell therapy | Inflammatory Bowel DiseaseGraft-versus-Host Disease Ulcerative Colitis, Crohn's Disease |
JR-131No recent activity | Phase 3 | Erythropoietin receptor (EPO-R)Biologic (subtype unspecified) | Chronic Kidney Disease |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
Est. primary completion 2026-12 · NCT01761968 · CT.gov ↗
What to watch
2028 (2)
Financial reports
No financial reports recorded.